Application of the Scleroderma Clinical Trials Consortium Damage Index in patients with juvenile systemic sclerosis

• DOI: 10.1186/s12969-025-01110-6
• Publication Date: 2025-05-14T17:27:49Z
• Authors: Caihui Zhang; Changyan Wang; Sihao Gao; Mingsheng Ma; Wei Wang; Tianyu Zhang; Yu Zhang; Xiaoyan Tang; Zhuo Li; Zhixing Sun; Lin Wang; Hongzhong Jin; Xiaofeng Zeng; Hongmei Song
• Keywords: Scleroderma (fungus); Systemic scleroderma

Juvenile systemic sclerosis (jSSc) can lead to permanent and irreversible anatomical or physiological dysfunction. The Scleroderma Clinical Trials Consortium-Damage Index (SCTC-DI), which has been employed validated in adult patients, quantify organ damage predict mortality morbidity. However, its application paediatric patients remains unexplored. data, laboratory results, prognostic information were collected for with jSSc at Peking Union Medical College Hospital (PUMCH) from January 2012 2024. Differences between the SCTC-DI juvenile severity score (J4S) recorded compared. Furthermore, we compared (SSc) patients. A total of 64 included. Facet joint contractures, fingertip ulcers interstitial lung disease are common manifestations. Compared SSc had a lower incidence gastrointestinal urinary system involvement. baseline J4S levels significantly correlated follow-up. higher was associated greater progression (P = 0.001). There differences clinical presentations be applied JSSc it is recommended that undergo regular evaluations as well SCTC-DI.